 It was approved by the U.S. Food and Drug Administration in December 2004 under the name "Prialt".Other drugs are in clinical and preclinical trials, such as compounds of the toxin that may be used in the treatment of Alzheimer's disease, Parkinson's disease, depression, and epilepsy.Many peptides produced by the cone snails show prospects for being potent pharmaceuticals, such as AVC1, isolated from the Australian species, the Queen Victoria cone, "Conus victoriae".